Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global E Online Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.49 (market cap $29.60B), while Global E Online Ltd trades at $40.64 (market cap $6.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GLBE | |
|---|---|---|
Market Cap | $29.60B | $6.87B |
Sector | Health | Technology |
52-Week High | $491.22 | $42.32 |
52-Week Low | $205.48 | $27.54 |
Enterprise Value | $27.56B | $6.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
GLBE trades at $39.76, down 3.38% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with revenue up 39% year-over-year and an adjusted EBITDA margin expansion to 20.9%. Recent news highlights the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorization.
The outlook is positive, with 100% buy ratings from analysts and a consensus price target of $44.75 implying 12.5% upside. Key opportunities include robust revenue growth and margin expansion, while risks involve high valuation multiples and insider selling activity. The stock's trajectory hinges on continued execution of its global e-commerce enablement strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
